SCHEMBL5779031

SCHEMBL5779031

CC(C)c1csc(CCl)n1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.38
MEN1 O00255 4/20 0.38
POLB P06746 1/20 0.38
RAB9A P51151 1/20 0.38
ALDH1A1 P00352 3/20 0.37
MAPK1 P28482 1/20 0.36
GAA P10253 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
CCR4 P51679 1/20 0.35
KDM4E B2RXH2 1/20 0.34
CYP1A2 P05177 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
GRM1 Q13255 1/20 0.33
DRD4 P21917 1/20 0.31
OGA O60502 1/20 0.30
ALB P02768 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8276154 0.81 MEN1 (0.39) KMT2AMEN1POLBRAB9AALDH1A1
SCHEMBL2644083 0.79 MEN1 (0.38) KMT2AMEN1POLBRAB9AALDH1A1
SCHEMBL2628923 0.79 KMT2A (0.44) KMT2AMEN1POLBRAB9AALDH1A1
SCHEMBL13986776 0.79 MEN1 (0.38) KMT2AMEN1POLBRAB9AALDH1A1
SCHEMBL9258490 0.79 KMT2A (0.38) KMT2AMEN1POLBRAB9AALDH1A1
SCHEMBL2644081 0.79 KMT2A (0.38) KMT2AMEN1POLBRAB9AALDH1A1
SCHEMBL5779345 0.79 KMT2A (0.38) KMT2AMEN1POLBRAB9AALDH1A1
SCHEMBL12120609 0.79 ALDH1A1 (0.40) KMT2AMEN1POLBRAB9AALDH1A1
SCHEMBL12844161 0.78 SLC6A3 (0.40) KMT2AMEN1POLBRAB9AALDH1A1
SCHEMBL12776037 0.76 KMT2A (0.36) KMT2AMEN1POLBRAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11129814-B2 Antimicrobial agents TAXIS PHARMACEUTICALS, INC. (US) 2021-09-28 US disclosed
US-11129814-B2 Antimicrobial agents TAXIS PHARMACEUTICALS, INC. (US) 2021-09-28 US disclosed
US-20180338957-A1 ANTIMICROBIAL AGENTS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2018-11-29 US disclosed
US-10071082-B2 Antimicrobial agents RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2018-09-11 US disclosed
US-20160367531-A1 ANTIMICROBIAL AGENTS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2016-12-22 US disclosed
US-20160367531-A1 ANTIMICROBIAL AGENTS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2016-12-22 US disclosed
US-20160367531-A1 ANTIMICROBIAL AGENTS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2016-12-22 US disclosed
US-9458150-B2 Antimicrobial agents RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2016-10-04 US disclosed
US-9458150-B2 Antimicrobial agents RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2016-10-04 US disclosed
US-9458150-B2 Antimicrobial agents RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2016-10-04 US disclosed
EP-1227084-B1 DRUG DISCHARGE PUMP INHIBITORS TRINE PHARMACEUTICALS INC (US) 2005-12-14 EP disclosed
US-20050009843-A1 Medicine for inhibiting drug elimination pump TRINE PHARMACEUTICALS, INC. 2005-01-13 US disclosed
EP-1389463-A1 MEDICINE FOR INHIBITING DRUG ELIMINATION PUMP DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-02-18 EP disclosed
US-20030092720-A1 Drug efflux pump inhibitor DAIICHI PHARMACEUTICAL CO., LTD (JP) 2003-05-15 US disclosed
CN-1414951-A Drug discharge pump inhibitor FUNDAMENTAL THERAPEUTICAL INC (US) 2003-04-30 CN disclosed
EP-1227084-A1 DRUG DISCHARGE PUMP INHIBITORS Microcide Pharmaceuticals, Inc. (US) 2002-07-31 EP disclosed
US-5455351-A Treating HIV or AIDS ABBOTT LABORATORIES (US) 1995-10-03 US disclosed
US-5290798-A Antihistamines, antiallergens, antiinflammatory agents MERCK FROSST CANADA, INC. (CA) 1994-03-01 US disclosed
WO-1993021168-A1 THIAZOLE-SUBSTITUTED BENZYL ALCOHOLS AS LEUKOTRIENE ANTAGONISTS MERCK FROSST CANADA INC. (CA) 1993-10-28 WO disclosed
EP-0535926-A1 (Hetero-arylmethoxy) indoles as inhibitors of leukotriene biosynthesis MERCK FROSST CANADA INC. (CA) 1993-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180338957-A1 ANTIMICROBIAL AGENTS MRPL21, SPOUT1, LSS KMT2A 4343/4885MEN1 3062/4885POLB 186/4885
US-11129814-B2 Antimicrobial agents MRPL21, SPOUT1, LSS KMT2A 4343/4885MEN1 3062/4885POLB 186/4885
US-20160367531-A1 ANTIMICROBIAL AGENTS CFTR, MRPL21, ARG1 KMT2A 4507/4885MEN1 1168/4885POLB 2530/4885
US-10071082-B2 Antimicrobial agents CFTR, MRPL21, ARG1 KMT2A 4507/4885MEN1 1168/4885POLB 2530/4885
US-20030092720-A1 Drug efflux pump inhibitor ABCB11, ABCB1, ABCC1 KMT2A 3288/4885MEN1 4800/4885POLB 3005/4885
US-20050009843-A1 Medicine for inhibiting drug elimination pump ABCB11, ATP6AP1, HRH2 KMT2A 3458/4885MEN1 3567/4885POLB 3610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.